Discipline of Pharmacology, School of Medical Sciences, Medical School, Frome Road, University of Adelaide, Adelaide, SA, Australia.
CNS Drugs. 2012 Nov;26(11):949-57. doi: 10.1007/s40263-012-0002-5.
The triptans are a group of compounds with high efficacy for the acute treatment of migraine and cluster headache. They have a relatively wide therapeutic index, and although a number of minor pharmacokinetic interactions have been observed, few are likely to be clinically significant. Given the differences in principal elimination pathways, potentially interacting drugs on a pharmacokinetic basis are not common across all compounds. Of more concern than pharmacokinetic interactions are pharmacodynamic interactions. Of most concern, additive vasoconstrictor effects are likely to occur with other vasoconstrictors, especially the ergots used for migraine. Serotonin syndrome has been observed due to coadministration of triptans with selective serotonin reuptake inhibitors (SSRIs), but the absolute rate of such a clinical response to coadministration is probably low. Most patients can take triptans with other medications without dose alteration, although vigilance is required for pharmacodynamic interactions.
曲坦类药物是一组化合物，对偏头痛和丛集性头痛的急性治疗具有很高的疗效。它们具有相对较宽的治疗指数，虽然观察到一些较小的药代动力学相互作用，但很少可能具有临床意义。鉴于主要消除途径的差异，在基于药代动力学的情况下，潜在相互作用的药物在所有化合物中并不常见。比药代动力学相互作用更值得关注的是药效动力学相互作用。最值得关注的是，与其他血管收缩剂（特别是用于偏头痛的麦角）联合使用可能会产生附加的血管收缩作用。由于曲坦类药物与选择性 5-羟色胺再摄取抑制剂（SSRIs）联合使用，已经观察到血清素综合征，但联合使用时出现这种临床反应的绝对比率可能较低。大多数患者可以在不改变剂量的情况下服用曲坦类药物，尽管需要注意药效动力学相互作用。
